Aprepitant Cap 2 x 80 mg and 1 x 125 mg: Supply issue

Supply issue Active

Merk Sharpe and Dohme have advised that there is a supply issue with their aprepitant cap (2 x 80 and 1 x 125mg) tri-packs (pharmacode 2244098).

Affected product

The Emmend Tri-Pack (aprepitant Cap 2 x 80 mg and 1 x 125 mg) is affected by this issue. 

Schedule listing for aprepitant(external link)

Expected resupply date

Stock has recently arrived in New Zealand, including a shipment that arrived on 29 June. The first shipment has been released and the second shipment is currently going through the manufacturer’s Quality Assurance process before release and distribution. This process is being expedited as a priority.

Unexpected issues have impacted the release of previously arrived stock and these are being worked through by the supplier.

Merck Sharpe and Dohme, Pharmac, and Healthcare Logistics (the logistics provider) are working to expedite the release and distribution as soon as possible. We expect that distribution of the first shipment would occur late in the week ending 1 July 2022. All parties are aware of the critical nature of this pharmaceutical.

Who to contact

If you have questions about the availability of this medicine, contact MSD New Zealand(external link)

If you have questions about the funding of this medicine, email enquiry@pharmac.govt.nz

When emailing us, please include as much information as you can about the product (presentation, brand, pharmacode) and who your wholesaler is.